Literature DB >> 17513061

Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings.

Ilwoo Park1, Gregory Tamai, Michael C Lee, Cynthia F Chuang, Susan M Chang, Mitchel S Berger, Sarah J Nelson, Andrea Pirzkall.   

Abstract

PURPOSE: To determine whether the combined magnetic resonance imaging (MRI) and magnetic resonance spectroscopy imaging (MRSI) before radiation therapy (RT) is valuable for RT target definition, and to evaluate the feasibility of replacing the current definition of uniform margins by custom-shaped margins based on the information from MRI and MRSI. METHODS AND MATERIALS: A total of 23 glioblastoma multiforme (GBM) patients underwent MRI and MRSI within 4 weeks after surgery but before the initiation of RT and at 2-month follow-up intervals thereafter. The MRSI data were quantified on the basis of a Choline-to-NAA Index (CNI) as a measure of spectroscopic abnormality. A combined anatomic and metabolic region of interest (MRI/S) consisting of T2-weighted hyperintensity, contrast enhancement (CE), resection cavity, and CNI2 (CNI >or= 2) based on the pre-RT imaging was compared to the extent of CNI2 and the RT dose distribution. The spatial relationship of the pre-RT MRI/S and the RT dose volume was compared with the extent of CE at each follow-up.
RESULTS: Nine patients showed new or increased CE during follow-up, and 14 patients were either stable or had decreased CE. New or increased areas of CE occurred within CNI2 that was covered by 60 Gy in 6 patients and within the CNI2 that was not entirely covered by 60 Gy in 3 patients. New or increased CE resided within the pre-RT MRI/S lesion in 89% (8/9) of the patients with new or increased CE.
CONCLUSION: These data indicate that the definition of RT target volumes according to the combined morphologic and metabolic abnormality may be sufficient for RT targeting.

Entities:  

Mesh:

Year:  2007        PMID: 17513061      PMCID: PMC2377157          DOI: 10.1016/j.ijrobp.2007.03.019

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  34 in total

1.  Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors.

Authors:  S J Nelson
Journal:  Magn Reson Med       Date:  2001-08       Impact factor: 4.668

Review 2.  Multivoxel magnetic resonance spectroscopy of brain tumors.

Authors:  Sarah J Nelson
Journal:  Mol Cancer Ther       Date:  2003-05       Impact factor: 6.261

3.  MR of the brain using fluid-attenuated inversion recovery (FLAIR) pulse sequences.

Authors:  B De Coene; J V Hajnal; P Gatehouse; D B Longmore; S J White; A Oatridge; J M Pennock; I R Young; G M Bydder
Journal:  AJNR Am J Neuroradiol       Date:  1992 Nov-Dec       Impact factor: 3.825

4.  An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.

Authors:  M D Walker; T A Strike; G E Sheline
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-10       Impact factor: 7.038

5.  Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms.

Authors:  P J Kelly; C Daumas-Duport; D B Kispert; B A Kall; B W Scheithauer; J J Illig
Journal:  J Neurosurg       Date:  1987-06       Impact factor: 5.115

6.  Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence.

Authors:  Tracy R McKnight; Mary H von dem Bussche; Daniel B Vigneron; Ying Lu; Mitchel S Berger; Michael W McDermott; William P Dillon; Edward E Graves; Andrea Pirzkall; Sarah J Nelson
Journal:  J Neurosurg       Date:  2002-10       Impact factor: 5.115

Review 7.  Spatial localization in NMR spectroscopy in vivo.

Authors:  P A Bottomley
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

8.  MR-spectroscopy guided target delineation for high-grade gliomas.

Authors:  A Pirzkall; T R McKnight; E E Graves; M P Carol; P K Sneed; W W Wara; S J Nelson; L J Verhey; D A Larson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-15       Impact factor: 7.038

9.  Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonance spectroscopy.

Authors:  Andrea Pirzkall; Sarah J Nelson; Tracy R McKnight; Michelle M Takahashi; Xiaojuan Li; Edward E Graves; Lynn J Verhey; William W Wara; David A Larson; Penny K Sneed
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-08-01       Impact factor: 7.038

10.  Assumptions in the radiotherapy of glioblastoma.

Authors:  F H Hochberg; A Pruitt
Journal:  Neurology       Date:  1980-09       Impact factor: 9.910

View more
  35 in total

1.  Clinical target volume delineation in glioblastomas: pre-operative versus post-operative/pre-radiotherapy MRI.

Authors:  P Farace; M G Giri; G Meliadò; D Amelio; L Widesott; G K Ricciardi; S Dall'Oglio; A Rizzotti; A Sbarbati; A Beltramello; S Maluta; M Amichetti
Journal:  Br J Radiol       Date:  2010-11-02       Impact factor: 3.039

2.  7-Tesla susceptibility-weighted imaging to assess the effects of radiotherapy on normal-appearing brain in patients with glioma.

Authors:  Janine M Lupo; Cynthia F Chuang; Susan M Chang; Igor J Barani; Bert Jimenez; Christopher P Hess; Sarah J Nelson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-10-12       Impact factor: 7.038

Review 3.  The Role of Standard and Advanced Imaging for the Management of Brain Malignancies From a Radiation Oncology Standpoint.

Authors:  Robert H Press; Jim Zhong; Saumya S Gurbani; Brent D Weinberg; Bree R Eaton; Hyunsuk Shim; Hui-Kuo G Shu
Journal:  Neurosurgery       Date:  2019-08-01       Impact factor: 4.654

Review 4.  Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.

Authors:  C von Neubeck; A Seidlitz; H H Kitzler; B Beuthien-Baumann; M Krause
Journal:  Br J Radiol       Date:  2015-07-10       Impact factor: 3.039

5.  Volumetric spectroscopic imaging of glioblastoma multiforme radiation treatment volumes.

Authors:  N Andres Parra; Andrew A Maudsley; Rakesh K Gupta; Fazilat Ishkanian; Kris Huang; Gail R Walker; Kyle Padgett; Bhaswati Roy; Joseph Panoff; Arnold Markoe; Radka Stoyanova
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-24       Impact factor: 7.038

6.  3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.

Authors:  Manickam Muruganandham; Patrick P Clerkin; Brian J Smith; Carryn M Anderson; Ann Morris; Aristides A Capizzano; Vincent Magnotta; Sarah M McGuire; Mark C Smith; John E Bayouth; John M Buatti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-06-28       Impact factor: 7.038

7.  Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme.

Authors:  Andrew Elson; Eric Paulson; Joseph Bovi; Malika Siker; Chris Schultz; Peter S Laviolette
Journal:  J Neurooncol       Date:  2015-04-17       Impact factor: 4.130

8.  Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer.

Authors:  Bang-Bin Chen; Yen-Shen Lu; Chih-Wei Yu; Ching-Hung Lin; Tom Wei-Wu Chen; Shwu-Yuan Wei; Ann-Lii Cheng; Tiffany Ting-Fang Shih
Journal:  Eur Radiol       Date:  2018-05-16       Impact factor: 5.315

9.  Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.

Authors:  Sarah J Nelson; Achuta K Kadambi; Ilwoo Park; Yan Li; Jason Crane; Marram Olson; Annette Molinaro; Ritu Roy; Nicholas Butowski; Soonmee Cha; Susan Chang
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

10.  Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI.

Authors:  Mekhail Anwar; Annette M Molinaro; Olivier Morin; Susan M Chang; Daphne A Haas-Kogan; Sarah J Nelson; Janine M Lupo
Journal:  Radiat Res       Date:  2017-07-19       Impact factor: 2.841

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.